Takeda Pharmaceutical Company, Limited

In 1781, the first Omiya Nagahiro, aged 32, began trading in traditional Japanese and Chinese medicines in Osaka's Michishirubacho, a central hub for pharmaceutical trade under the shogunate's license. He purchased medicines from wholesalers, divided them into smaller portions, and sold them to local drug merchants and physicians. This small wholesale shop became the beginning of what is now Takeda Pharmaceutical.

In 1781, the first generation, Omiya Chōbei, started a business trading traditional Chinese and Japanese medicines in Osaka, the center of Japan's drug trade, under the license of the shogunate. It was a small drug wholesaler that bought medicines from wholesalers, divided them into small portions, and sold them to local drug merchants and doctors. This became the beginning of today's Takeda Pharmaceutical.

The third Nagahiro demolished the old mansion at the southeast corner of Naka-bashi Street in Michishirubacho and built a new residence and storage. This building remained for about 75 years until the construction of the head office building began in Showa 2 (1927).

The fourth Nagahiro (who changed his surname from Omiya to Takeda around the time the Family Register Act was enacted) focused on Western medicines before his contemporaries, forming a procurement cooperative for Western drugs in Yokohama with close associates and began trading with foreign trading houses. Imported Western medicines at the time included quinine for malaria and coal tar for cholera. The number of imported Western drugs increased from 18 items initially to 146 items over the next decade.

In 1895, Takeda established its own dedicated factory, the Nairin Pharmaceutical Plant, in Osaka, becoming a pharmaceutical manufacturer. Products produced at the plant included lead-based preparations and hydrochloride quinine. In 1907, it became the first in Japan to successfully manufacture saccharin.

Sagi Brand

During World War I, imports from Germany were cut off, so Takeda released a series of its own products such as 'Calmotin' (sedative), 'Novorform' (analgesic), and 'Rodion' (glucose injection). Additionally, significant changes occurred in overseas trade, and the company began exporting pharmaceuticals to the United States, Russia, and China.

Shortly after starting the pharmaceutical business, Takeda established a testing department, and in 1915 founded a research department to develop new drugs and conduct pharmaceutical research. The research and development system formed during this period became the foundation that led Takeda to growth.

In the Michishirubacho area, the shop roofs were removed to widen the street, and the area was paved with wooden bricks.

Established Takeda Nagahiro Shoten Co., Ltd. (capital 5.3 million yen, president Gōdai Takeda Nagahiro). With this, the company transitioned from a sole proprietorship to a modern corporate organization integrating research & development, manufacturing, and sales. In 1943, the company name was changed to the current Takeda Pharmaceutical Co., Ltd.

Collecting and utilizing medicinal and useful plants from around the world, the company currently holds over 2,882 species, including 104 endangered species. The original name at establishment was "Kyoto Takeda Herb Garden". It was renamed "Kyoto Experimental Farm" in 1945, and since 1994 it has been known by its current name.

Established the "Kyoto Medicinal Plant Garden." It collects and utilizes medicinal and useful plants from around the world, currently holding over 2,882 species, including 104 endangered species.

Changed the company name to the current Takeda Pharmaceutical Company Limited in 1943.

Established the Fermentation Research Institute.

Established the "Fermentation Research Institute." It has supported research as a microorganism stock preservation organization for 60 years. Currently, it conducts grants for microbiological research.

Opened the Light Factory. The former Yamaguchi Prefecture Light Naval Factory, which had been devastated by heavy bombing just before the end of the war, was repurposed as a factory under GHQ permission. This became the first postwar private use of former national land. The factory became the second major plant after Osaka, producing items such as vaccine preparations that were in demand by society at the time.

Established the Hikari Factory. It was converted into a factory under the permission of GHQ on the site of the Hikari Naval Arsenal in Yamaguchi Prefecture, which was destroyed by a fierce bombing just before the end of the war. This was the first use of national land by the private sector after the war. The factory became the second main factory after Osaka and produced vaccines and other products in response to social demands at the time.

On May 20, 1946, Takeda was invited by the city of Hikari in Yamaguchi Prefecture and established the Hikari Factory on the vast former naval shipyard site.

Manufacturing at the Hikari Factory began in July 1946, and the first shipment was made in January of the following year, marking the first pharmaceutical product shipped from the Hikari Factory.

The first shipment was made in January of the following year, marking the first pharmaceutical product shipped from the Hikari Factory.

Listed on the Tokyo and Osaka Stock Exchanges in May.

Listed shares on the Tokyo and Osaka Stock Exchanges, becoming a listed company in May.

Released "Panvitamin", the first comprehensive vitamin supplement in Japan.

Established Japan Redley Co., Ltd. through a 50-50 joint venture. A 50-50 joint venture with American Sianamid Co. established Japan Redley Co., Ltd. (now Wais Co., Ltd.), becoming the first postwar pharmaceutical joint venture company. The company manufactured the antibiotic "Oreo Mycin", and Takeda was responsible for its sales.

Established Nihon Redali Co., Ltd. with a joint capital contribution. It was the first post-war pharmaceutical joint venture. The company manufactured the antibiotic "Oleomycin," and Takeda was responsible for sales of the product.

Successfully developed and began selling "Arinamin", a vitamin B1 derivative formulation that enhances the absorption of vitamin B1 in the body. Around the same time, the company started supplying fortified vitamins to address postwar nutritional deficiencies caused by food shortages.

The Hikari Factory began manufacturing Japanese encephalitis vaccine in 1954, before the outbreak.

The product 'Alinamin', derived from the discovery that allicin becomes a component of a vitamin B1 derivative, began sales in 1954. It was sold not only domestically but also in countries worldwide, and the Hikari Factory established new production lines to increase output.

The plant was completed in June 1954 and began operation in July of the same year.

It began operation in July of that year.

Rooted in the 1923 initiative by Gōdai Takeda Nagahiro, who invested his own money to support struggling students, the company evolved into "Nōshisha" in 1960, dedicated to educational support.

In the post‑war period, demand for vitamin C was rising worldwide. Accordingly, a large vitamin C manufacturing plant was built at the Hikari Factory, which had ample land and water resources. This facility was the first at the Hikari Factory to have a central instrumentation room and employed a centralized control system. It was a very advanced large plant for the pharmaceutical industry of that era.

The second plant, with about four times the capacity of the first plant completed in 1961, was built. In 1973, a third plant was added. Each new plant incorporated the latest technology, advancing continuous production and automation.

In 1961, the 180th anniversary of the founding, a design based on the original 'Hugiyama-Hon' created at the time of founding was made. During a period when import/export and overseas expansion were active, the 'Takeda' brand was recognized by patients and medical professionals worldwide. The original mountain motif, which was straight, was changed to a rounded design to symbolize trust, creating the 'Hugiyama'.

Starting with the establishment of a manufacturing and sales company in Taiwan in 1962, the company subsequently set up manufacturing and sales subsidiaries in Southeast Asian countries such as the Philippines, Thailand, and Indonesia. The Tianjin Takeda Pharmaceutical Co., Ltd., established in 1994, became China’s first GMP‑compliant factory.

Established as a foundation funded by donations from Takeda, with the purpose of supporting and promoting scientific and technological research, and contributing to the advancement of science, technology, and culture.

Established the "Takeda Science Foundation." It was established to promote scientific and technological research and contribute to the advancement of science, technology, and culture, funded by donations from Takeda.

The vitamin B1 plant was completed and production began. The product 'Alinamin', derived from the discovery that allicin becomes a component of a vitamin B1 derivative, began sales in 1954. It was sold not only domestically but also worldwide, and the Hikari Factory established new production lines to increase output.

Derived from the discovery that allicin, a component of garlic, becomes a component of a vitamin B1 derivative, 'Alinamin' began sales in 1954. It was sold not only in Japan but also in countries around the world, and the Light Factory established new manufacturing lines to prepare for increased production.

Demand for vitamin C continued to grow, and the Hikari Factory expanded its vitamin C manufacturing plant accordingly. The second plant, with about four times the capacity of the first plant completed in 1961, was built. In 1973, a third plant was added. Each new plant incorporated the latest technology, advancing continuous production and automation.

The dry low-toxicity measles vaccine is the first product of the Light Factory's live vaccine production. Live vaccines, which require advanced technology, use a virus that has had its toxicity weakened and pathogenicity eliminated as the raw material. The virus replicates in the body, and as a result, immunity increases.

In Japan from the late 1960s to the early 1970s, industrialization and urbanization progressed, environmental problems worsened, and laws aimed at environmental protection, such as the Basic Law for Environmental Pollution Control (1967), were enacted. The Light Factory also established an environmental protection division and set up new facilities to prevent air pollution and water contamination. Measures to prevent noise and odor, as well as thorough consideration for residents in the area, have continued to protect the rich natural surroundings around the Light Factory to this day.

Penicillin is a drug used to treat bacterial diseases such as pneumonia and syphilis, and it was purified using fermentation technology. One of the penicillin-type antibiotics produced by the Light Factory, 'Rilasin', was manufactured by chemical synthesis rather than fermentation. The production of synthetic penicillin was a first in Japan, contributing to many patients in need of this drug and becoming a flagship product for Takeda.

In 1973, a third plant was established.

Following the establishment of a pharmaceutical sales joint venture in France in 1978, the company opened bases in Germany and Italy by 1982.

Expanded into Europe. Following the establishment of a joint pharmaceutical sales company in France, it also established bases in Germany and Italy.

'Cefotiam hydrochloride' and 'Cefuroxime sodium' are both drugs called cephalosporin antibiotic preparations. Cephalosporin antibiotics exert bactericidal effects by inhibiting the function that builds bacterial cell walls. Demand for cefotiam hydrochloride increased, leading to its production at a large-scale factory. Cefuroxime sodium was the first antibiotic for which Takeda passed an FDA inspection in the injectable drug field.

A new factory was established to manufacture powder injectable antibiotics that are dissolved in liquid when injected, and production of cephalosporin antibiotic preparations such as 'Cefuroxime sodium' and 'Cefmenoxime hydrochloride' began. This new factory established systems for sterile product manufacturing, quality control, and testing.

Completion of manufacturing equipment for antibiotic powder injectables, production commenced. A factory was established to produce powder injectable antibiotics that are dissolved in liquid when injected, and production of cephalosporin antibiotic preparations such as 'Cefuroxime sodium' and 'Cefmenoxime hydrochloride' began. This new factory established systems for sterile product manufacturing, quality control, and testing.

In 1985, a joint venture with Abbott in the United States established TAP Pharmaceuticals Inc. (later TAP Pharmaceutical Products Inc.; split in 2008 and merged with Takeda Pharmaceuticals North America Inc.). In the same year, the company launched its own prostate cancer treatment drug "Luproline" (generic name: leuprolide).

In 1985, the company released "Luproline", incorporating the results of DDS (drug delivery system) research into a one‑injection, one‑month sustained‑release leuprolide formulation called "Luproline Depot", which was launched in the United States and Europe. It is now sold in about 80 countries worldwide and has become the standard drug for prostate cancer treatment. A formulation that maintains therapeutic effect for up to four months with a single injection has also been launched in the United States.

Leuprorelin acetate was released in 1985 as a drug used to treat endometriosis and prostate cancer. Since then, in response to expanding demand domestically and abroad, large-scale production began at the Light Factory. In addition to leuprorelin acetate, drugs such as lansoprazole, candesartan, and pioglitazone also began sales in overseas markets, increasing demand for the Light Factory.

Established a joint venture with Abbott in the United States, TAP Pharmaceuticals Co., Ltd. (later TAP Pharmaceutical Products Co., Ltd.). Same year, launched prostate cancer treatment drug "Lupron (generic name: Leuprorelin)."

Established the Tsukuba Research Center, a second research site following the Osaka laboratory, conducting basic research using cutting‑edge technology.

As the number of candidate development substances increased, the need to further strengthen the safety assessment system conducted at the research institute grew. Therefore, the Light Factory established the Light Branch of the Drug Safety Research Institute. It was responsible for long-term safety testing, securing rapid and reliable data, and contributing to the improvement of safety assessment capabilities for candidate development compounds.

Further strengthening of the drug safety assessment system. As the number of candidate development substances increased, the need to further enhance the safety assessment system conducted at the research institute grew. Therefore, the Light Factory established the Light Branch of the Drug Safety Research Institute. It was responsible for long-term safety testing, securing rapid and reliable data, and contributing to the improvement of safety assessment capabilities for candidate development compounds.

Established Tsukuba Research Center. Conducts basic research using cutting-edge technology as a second research base following the Osaka laboratory.

In 1989, launched a one‑month extended‑release formulation of leuprolide (generic name) in the United States and Europe.

In 1989, launched a one‑month extended‑release formulation of leuprolide (generic name) in the United States and Europe. The 1985 release of "Luproline" incorporated DDS (drug delivery system) research results into a one‑injection, one‑month sustained‑release leuprolide formulation called "Luproline Depot", which was launched in the United States and Europe. It is now sold in about 80 countries worldwide and has become the standard drug for prostate cancer treatment. A formulation that maintains therapeutic effect for up to four months with a single injection has also been launched in the United States.

In 1989, launched a one-month sustained-release formulation of Leuprorelin (generic name) in the U.S. and Europe.

In 1989, launched a one-month sustained-release formulation of Leuprorelin (generic name) in the U.S. and Europe.

Launched a one-month sustained-release formulation of "Leuprorelin (generic name)" in the US and Europe. Incorporates DDS research成果 into the traditional "Lupron" and sells a formulation with effects lasting one month.

Production of the company’s own luteinizing hormone-releasing hormone derivative, 'Leuprorelin acetate', began. It is used domestically and abroad to treat conditions such as endometriosis and prostate cancer.

Leuprorelin acetate production commenced. Production of the company’s own luteinizing hormone-releasing hormone derivative, 'Leuprorelin acetate', began. It is used domestically and abroad to treat conditions such as endometriosis and prostate cancer.

In 1991, launched the gastric ulcer treatment drug "Lansoprazole" (generic name) in Europe. The company’s own proton‑pump inhibitor "Lansoprazole" (generic name) began sales in Europe, followed by Japan, Asia, and the United States. It is now sold in about 90 countries worldwide. Subsequently, the global sales of "Leuprolide" (Leuproline) and "Lansoprazole" (Takipro) both exceeded 100 billion yen, significantly increasing the company’s overseas sales proportion. At the same time, the company strengthened its business base in Europe and the United States and accelerated internationalization.

Production of the company’s own proton pump inhibitor, 'Lansoprazole', began. It is used domestically and abroad as a treatment for gastric ulcers.

Lansoprazole production commenced. Production of the company’s own proton pump inhibitor, 'Lansoprazole', began. It is used domestically and abroad as a treatment for gastric ulcers.

In 1991, launched the treatment for peptic ulcers, Lansoprazole (generic name), in Europe. Started sales of the self-developed proton pump inhibitor Lansoprazole (generic name) in Europe, Japan, Asia, and the U.S. Currently, it is sold in about 90 countries worldwide. Subsequently, the global sales of Leuprorelin (Leuproline) and Lansoprazole (Takpro) exceeded 100 billion yen each, significantly increasing the company's overseas sales ratio. At the same time, the company strengthened its business foundation in Europe and America, and advanced internationalization.

Launched the anti-ulcer drug "Lansoprazole (generic name)" in Europe. Launched the type 2 diabetes treatment "Nesina" in the US to lower blood sugar levels.

New manufacturing equipment was established for the cephalosporin antibiotic 'Cefazolin hydrochloride', a powdered drug produced using freeze-drying technology.

Completion of manufacturing equipment using freeze-drying technology for antibiotics. New equipment was established for the cephalosporin antibiotic 'Cefazolin hydrochloride', a powdered drug produced using freeze-drying technology.

In 1995, established "ELI Takeda". Founded under the management philosophy of "a company that loves people with disabilities who work", it was the first special subsidiary in the pharmaceutical industry dedicated to employing people with disabilities.

Leuprorelin acetate bulk manufacturing equipment completed. In response to increased demand from the launch of the once-every-four-weeks injectable formulation of 'Leuprorelin acetate', production capacity for the active ingredient was expanded.

In 1995, established 'ELAI Takeda.' It is a special subsidiary aimed at employing people with disabilities, founded under the management philosophy of loving working people with disabilities, and is the first in the pharmaceutical industry.

Established "Eli Takeda."

Completion of bulk manufacturing expansion facility for lansoprazole. In response to increased sales volume, we established new equipment to expand the production of the active pharmaceutical ingredient.

Start of candesartan production. Production of our in-house developed angiotensin II receptor antagonist "candesartan" has begun. It is used as an antihypertensive drug domestically and abroad.

Transition to a company system. To accelerate decision-making and enhance organizational strength, we introduced a company system. In the Kō factory, the Food & Vitamin Manufacturing Division, which grew into a major business, was renamed "Food & Vitamin Company Kō Manufacturing Division"; the Agro Manufacturing Division became "Agro Company Kō Manufacturing Division"; and the Tokuyama satellite plant was renamed "Chemical Company Tokuyama Plant", separating them from the Kō factory.

50th Anniversary of Kō Factory Commencement Ceremony. On May 20, a ceremony was held to commemorate the 50th anniversary of the Kō factory's opening. At the ceremony, a donation was presented to Kō City in support of the local community. As part of the commemorative project, all employees planted 1,776 umbrella trees (Uba megashi) on the coastal landfill, one each. In the Kō factory courtyard, guests including the mayor of Kō City planted 22 trees, promoting environmental conservation in partnership with Kō City.

1997: Released the antihypertensive drug "candesartan cilexetil (generic name)" in Europe. Began selling the company‑developed "candesartan cilexetil (generic name)" in the UK and Germany. As an angiotensin II receptor antagonist that creates a new trend in hypertension treatment, it is now sold in about 60 countries worldwide.

1997: Established UK Takeda Limited, a wholly‑owned pharmaceutical sales company in the United Kingdom.

1997: Established Takeda Ireland Limited, a pharmaceutical manufacturing plant.

1997: Established Takeda America Research & Development Center Inc. in the United States.

1997: Established Takeda America Holdings Inc., a holding company for the medical pharmaceutical business in the United States.

In 1997, launched Candesartan Cilexetil (generic name), an antihypertensive drug, in Europe. Started sales of the self-developed Candesartan Cilexetil (generic name) in the UK and Germany. As an angiotensin II receptor antagonist creating a new trend in hypertension treatment, it is now sold in about 60 countries worldwide.

In 1997, established Takeda Limited, a wholly owned pharmaceutical sales company in the UK.

In 1997, established Takeda Ireland Limited, a pharmaceutical manufacturing plant. As the overseas sales ratio increased, a manufacturing base for formulations was established in Ireland in addition to the domestic production base.

In 1997, established Takeda America Research & Development Center Inc. in the U.S.

In 1997, established Takeda America Holdings Inc., a holding company for the pharmaceutical business in the U.S.

Launched the hypertension drug "Candesartan Cilexetil (generic name)" in Europe. Established Takeda Limited, a fully owned pharmaceutical sales company in the UK. Established Takeda America Research and Development Center Inc. and a holding company for prescription drugs business in the US.

1998: Established Takeda Pharmaceuticals America Inc., a wholly‑owned sales subsidiary in the United States.

1998: Established Takeda Europe Research & Development Center Inc. (now Takeda Global Research & Development Center (Europe) Inc.).

Obtained ISO 14001 Environmental Management System certification.

In 1998, established Takeda Pharmaceuticals America Inc. as a wholly owned sales base in the U.S. Started sales of the self-developed type 2 diabetes drug Actos from the following year.

In 1998, established Takeda Europe Research & Development Center Inc. (now Takeda Global Research & Development Center Europe Inc.).

Established Takeda Pharmaceuticals America Inc. as a fully owned sales base in the US. Established Takeda Europe Research and Development Center Inc.

1999: Released the diabetes treatment drug "Actos" (generic name pioglitazone). The company‑developed insulin resistance improvement drug "Actos" was launched in the United States and Japan. The following year, it was also sold in Asia and Europe.

Start of pioglitazone production. Production of our in-house developed insulin resistance improving drug "pioglitazone" has begun. It is used as a diabetes treatment drug domestically and abroad.

In 1999, launched the diabetes drug Actos (generic name Pioglitazone). Started sales of the self-developed insulin resistance improving drug Actos in the U.S. and Japan. It was also sold in Asia and Europe the following year.

Launched the diabetes drug "Actos (generic name: Pioglitazone)" in the US and Japan.

2000: Began restructuring the non‑pharmaceutical business. By 2006, the restructuring of the animal drug, vitamin, chemical, food, pesticide, and lifestyle environment businesses was completed.

In 2000, began restructuring the pharmaceutical external business. By 2006, restructured the animal drug, vitamin, chemical, food, agricultural chemical, and environmental health businesses.

Started restructuring the pharmaceutical external business. Reorganized animal drug, vitamin, chemical, food, pesticide, and environmental businesses by 2006.

2002: Acquired the management rights of Takeda Pharma GmbH and established Takeda Ireland Pharmaceuticals Inc., a raw material manufacturing plant.

In 2002, acquired management rights of Takeda Pharma GmbH and established Takeda Ireland Pharmaceuticals Inc., a raw drug manufacturing plant.

Acquired management rights of Takeda Pharma GmbH. Established Takeda Ireland Pharmaceuticals Inc. to manufacture active pharmaceutical ingredients. Acquired and established a sales joint venture in Germany and an active pharmaceutical ingredient factory.

Integrated the U.S. biotech venture Silix Corporation into our global research and development network and renamed it Takeda San Diego Inc. Silix Corporation possessed high‑speed protein X‑ray crystallography technology, and this integration established our first U.S. research site.

Roserel (generic name: Ramelteon) is a melatonin receptor agonist that induces natural, physiological sleep, differing in mechanism of action from conventional insomnia treatments. It provides sleep without relying on anxiolytic or sedative effects.

Integrated US biotech venture Cyrix. Launched Rozerem in the US.

To strengthen our business base in Europe, we established a sales management company in London, United Kingdom, to comprehensively oversee the Takeda Group's sales companies in six European countries.

As one of the culminations of the intensification of our U.S. business since the mid‑1970s, and as a foundation for further strengthening our presence in the United States, we completed new headquarters for Takeda Pharmaceuticals North America Inc. and Takeda Global Research & Development Center Inc.

Our company has been publishing annual reports as "integrated reports" that incorporate not only financial information but also non‑financial information such as human rights, environmental, and community initiatives. The CSR Data Book is a re‑edited version that adds more detailed information to the annual report to further fulfill our accountability regarding non‑financial data. To minimize environmental impact, it is produced only in PDF and e‑book formats.

By 2006, restructured the pharmaceutical external business including animal drugs, vitamins, chemicals, foods, pesticides, and environmental health.

Established Takeda Pharmaceuticals Europe in the UK. Completed new building in the US. Integrated CSR report into the annual report.

We integrated Paradigm Therapeutics Ltd. in the United Kingdom and its Singapore subsidiary to further develop and strengthen our multi‑IND engine. Paradigm Therapeutics was founded in 1999 by researchers from Cambridge University, and many of its focus disease areas align with ours. Paradigm Therapeutics and its Singapore subsidiary were renamed Takeda Cambridge Ltd. (TCB) and Takeda Singapore Ltd. (TSP), respectively.

Based on an agreement with Abbott, we carried out a spin‑off of TAP Inc., which became a wholly‑owned subsidiary of our company. In July of the same year, we merged TAP Inc. into Takeda Pharmaceuticals North America Inc. (TPNA) and consolidated TAP's development functions into Takeda Global Research & Development Center Inc. (TGRD).

Millennium Pharmaceuticals is one of the world's leading biopharmaceutical companies, possessing a powerful research and development pipeline in oncology. In terms of research capabilities, it is a pioneer in the protein homeostasis field, having developed drug‑target discovery through innovative research. Millennium's outstanding knowledge, technology, and experience in oncology complement ours closely, creating significant synergistic effects.

Established Takeda Pharmaceuticals Asia Inc. and Takeda Clinical Research Singapore Inc.

Towards energy fuel conversion and reduction of greenhouse gas emissions.

In 2008, the Kyoto Protocol set targets for reducing greenhouse gas emissions. At the Kō factory, we also aimed to reduce carbon dioxide emissions, a type of greenhouse gas, by converting the fuel used from heavy oil to city gas, achieving a significant reduction in CO₂ emissions.

Subsequently, in 2009, we integrated Takeda Ireland Inc., the formulation and packaging plant.

Dexlant (generic name: Dexlansoprazole) is a proton pump inhibitor that, for the first time, achieves a formulation design where the drug is released in two stages with a time delay. It strongly and continuously suppresses gastric acid secretion.

Eurylix (generic name: Febuxostat) is a gout and hyperuricemia treatment developed by E-Mer Pharma. By inhibiting the enzyme that synthesizes uric acid, it demonstrates excellent uric acid‑lowering effects.

We support the 10 principles comprising "Human Rights," "Labor," "Environment," and "Anti‑Corruption" and incorporate them into all corporate activities. Additionally, we have established a dedicated CSR organization to enhance Takeda's CSR activities.

Received the PRTR Grand Prize 2008 Best Award for efforts in chemical management and risk communication.

Achieved zero emission by aiming to reduce waste and increase recycling rates.

Our company supports activities that increase access to health care for people in developing countries from a long‑term, continuous perspective. Through the World AIDS, Tuberculosis, and Malaria Fund (World Fund), we have implemented the Takeda Initiative, a donation program that supports the training of health care personnel in three African countries, for ten years starting in 2010. For example, in Nigeria, a personnel development support program funded by the Takeda Initiative trained more than 11,000 teachers in 2012, and over 1.2 million students received HIV education from those trained teachers. Such efforts have contributed to a downward trend in the HIV prevalence among Nigerian youth.

To conduct more unified business operations globally, we have established the Takeda Global Code of Conduct as a basic compliance rule common to all group companies.

Employees of the Kō factory also participated in activities carried out by companies and organizations around the Seto Inland Sea, such as cleaning rivers and beaches that flow into the sea.

Received the Minister of Health, Labour and Welfare Award for promoting reduce, reuse, and recycle.

Supports activities to improve healthcare access for people in developing countries from a long-term and continuous perspective. Implements the 'Takeda Initiative,' a donation program to support the development of healthcare personnel in three African countries through the Global Fund to Fight AIDS, Tuberculosis and Malaria, over ten years starting in 2010.

Established the 'Takeda Global Code of Conduct' as a basic rule of compliance shared across group companies.

Participated in the 30 million Setouchi Sea Clean-up Campaign. Employees of Hikari Factory participated in activities such as cleaning rivers and beaches around the Seto Inland Sea.

Agilva (generic name: Agilsartan) is a novel angiotensin II receptor blocker (ARB). In clinical trials, it has shown superior blood pressure‑lowering effects compared with existing ARBs.

The Shonan Research Institute was born by merging Osaka's Jusan Research Institute and Tsukuba Research Institute. As a global research hub that accelerates drug discovery innovation, it brings together about 1,200 researchers who work on nonclinical research from target discovery in the early stages of the R&D process to candidate compound selection and market launch.

In September 2011, we completed the integration of Swiss pharmaceutical company NAIKOMED. NAIKOMED is a company with a strong presence in Europe and emerging markets, and through this integration, Takeda expanded its distribution network to more than 70 countries, enhancing its sales infrastructure and expertise to deliver medicines to more patients and healthcare professionals worldwide.

Since January 2011, our company has been a member of the UN Global Compact's LEAD Program, leading activities to promote and implement the 10 principles of "Human Rights," "Labor," "Environment," and "Anti‑Corruption" alongside about 60 global companies.

We have been supporting the long‑term, continuous recovery of the areas affected by the Great East Japan Earthquake by donating a portion of the profits from Arinamin.

Hosted an in-company market to support reconstruction after the Great East Japan Earthquake.

Start of azilsartan production. Production of our in-house developed angiotensin II receptor antagonist "azilsartan" has begun. It is used as an antihypertensive drug domestically and abroad.

Since January 2011, as a member of the UN Global Compact's "LEAD Program," we have been promoting activities to lead the practice and dissemination of the 10 principles consisting of "Human Rights," "Labor," "Environment," and "Anti-Corruption" together with about 60 global companies.

A part of the revenue from Arinamin is donated as a contribution to support the long-term and continuous reconstruction of the affected areas of the Great East Japan Earthquake.

Held a "Company-in-Marche" to support the reconstruction of the Great East Japan Earthquake. To support the affected areas of the earthquake that occurred that year, a "Company-in-Marche" was held at Hikari Factory to sell specialty products from Tohoku and Kanto regions to employees. Such reconstruction and regeneration support programs are ongoing, and many employees participate.

Launched Azilva in Japan. Opened Shonan Research Institute. Integrated Naicomed. Participated in the UN Global Compact "LEAD Program". "Revitalize Japan & Support Reconstruction."

In September 2011, completed the integration of Swiss pharmaceutical company Nycomed. Nycomed is a company with a high presence in Europe and emerging markets. This integration expanded Takeda's sales network to over 70 countries and enhanced the sales system and expertise to deliver pharmaceuticals to more patients and healthcare professionals worldwide.

Established the Vaccine Business Division.

Released Adseveris (generic name: Brentuximab Vedotin) in Europe in 2012.

Our company signed a statement of support in December 2012.

We established the Vaccine Business Department.

We launched Adcetris (generic name: Brentuximab Vedotin) in Europe (2012).

Established Vaccine Business Division. Integrated four companies (URL Pharma, Multilab, Rigosite, Emboy). Formulated "Global EHS Policy." Launched Adcetris in Europe.

Our company signed a support statement in December 2012.

Rotrig (generic name: Omega‑3 fatty acid ethyl ester) is a high‑concentration omega‑3 fatty acid formulation introduced from Pronova. It is the first medical product in Japan to contain both EPA and DHA.

Nesina (generic name: Alogliptin besylate) is a type 2 diabetes treatment developed by Takeda California Inc. that lowers blood glucose by inhibiting the enzyme DPP‑4, which degrades the insulin‑secreting hormone glucagon‑like peptide‑1 (GLP‑1).

Through the acquisition of Inbivagen Inc. (USA), we acquired innovative pipelines and live and inactivated vaccine platform technologies, significantly enhancing our presence in the global vaccine market.

This is an antidepressant for adults introduced from Denmark's Lundbeck. With a pharmacological action different from existing drugs, it is expected to contribute to the treatment of depression for many patients.

Established a disaster prevention center to serve as a base for disaster response activities during large-scale disasters. It is also used as a stockpile base for supplies needed for disaster victim relief.

Start of bonoprazan fumarate production. Production of our in-house developed proton pump inhibitor "bonoprazan fumarate" has begun. It is used to treat acid-related diseases.

Trintellix (from Danish company Lundbeck) is expected to contribute to the treatment of depression in many patients due to its different pharmacological action from existing drugs.

Launched Lotriga in Japan. Launched Nesina in the US. Supports Women’s Empowerment Principles (WEPs). Integrated Inviragen.

Released Adseveris (generic name: Brentuximab Vedotin) in Japan in 2014.

Entyvio (generic name: Vedolizumab) is a groundbreaking product that provides a new treatment option for patients with inflammatory bowel disease who did not respond to existing therapies, and Takeda launched it in Europe and the United States in June 2014.

In April 2009, a novel influenza outbreak occurred around the United States and Mexico, and it also spread in Japan during the summer of that year. At that time, domestic vaccine production could not keep up, and the situation required emergency imports from overseas. Even Takeda, which had withdrawn from the influenza vaccine business, resumed production at the Kō factory to contribute to stable vaccine supply. A manufacturing and sales approval application was submitted in March 2013, and approval was obtained in April of the following year.

We launched Adcetris (generic name: Brentuximab Vedotin) in Japan (2014).

Launched Entivio in Europe and the US. Integrated four companies (Korkris, Multilab, Rigosite, Emboy).

Entyvio (generic name: Vedolizumab) is a groundbreaking product that provides a new treatment option for patients with inflammatory bowel disease who have not responded to existing therapies, and Takeda launched it in Europe and the US in June 2014.

The multiple myeloma treatment "Ninrola" was launched in the United States in 2015 as the world's first oral proteasome inhibitor.

Takeda and the Kyoto University iPS Cell Research Institute (CiRA Saira) have launched the joint research program T-CiRA for the clinical application of iPS cell technology.

The multiple myeloma treatment drug 'Ninlaro' was launched in the United States in 2015 as the world's first oral proteasome inhibitor. Ninlaro is a product derived from Nobel Prize–winning science and technology, developed through decades of multiple myeloma research.

Ninlaro (multiple myeloma treatment) was launched in the US in 2015 as the world's first oral proteasome inhibitor.

Takeda and Kyoto University iPS Cell Research Institute (CiRA) have started a joint research program T-CiRA for the clinical application of iPS cell technology.

Launched Ninlaro in the US. Started T-CiRA at Shonan Research Institute.

In 2016, the product name was changed from Brintellix to Trintellix.

Changed product name to Brintellix.

AriaD PharmaSuticals was integrated. This integration added solid tumors to Takeda's global portfolio and strengthened its oncology pipeline.

Start of production of the biologic drug "bedrizumab (genetically engineered)". It is used as a treatment for inflammatory bowel disease domestically and abroad.

Integrated Ariad Pharmaceuticals.

Shonan Health Innovation Park (Shonan I-Park) is Japan's first pharmaceutical company–led ecosystem, creating the latest healthcare solutions in an open and innovative environment.

Takeda Global Headquarters (Tokyo) was grand‑opened. It is designed to be a workplace environment that fosters diverse work styles and creative work.

Takeda became the only pharmaceutical company listed on both the Tokyo Stock Exchange and the NYSE.

When the manufacturing and sales approval for the 2014 novel influenza vaccine was obtained, the Kō factory had equipment capable of producing 25 million doses of vaccine. In 2015, an additional 8 million doses were decided to be produced, prompting the start of production system organization. Equipment expansion was completed in 2018.

Consolidated manufacturing and packaging of solid dosage forms at the Kō factory.

Opened Shonan Health Innovation Park. Grand opening of the global headquarters. Listed on the New York Stock Exchange.

Shire was integrated. Takeda became a global leading company in research‑driven biopharmaceuticals with operations in about 80 countries and regions.

The TAKEDA LIFE THEATER was opened. The TAKEDA LIFE THEATER was opened on the first floor of Takeda Global Headquarters, contributing to community health and wellness.

Shire was integrated. TAKEDA LIFE THEATER was opened.

The unified 'Hugiyama' was adopted as the corporate brand symbol for Takeda worldwide.

The novel coronavirus disease (COVID-19) has shown a global pandemic. We are responsible for the rapid import of vaccines that have been approved by the Pharmaceuticals and Medical Devices Agency after clinical trials in Japan, and for domestic distribution under strict temperature control. Furthermore, Takeda is building and preparing to operate its own manufacturing facilities for COVID-19 vaccines. The manufacturing line, developed through technology transfer from U.S. pharmaceutical company Novavax, utilizes biotechnologies cultivated at our light factory.

In June 2021, Takeda celebrated its 240th anniversary. The company remains committed to putting patients at the center and acting with integrity. The values that have guided the company since its founding remain unchanged to this day.